ALEXION 3Q: Soliris sales rise 36%, pipeline progresses
This article was originally published in Scrip
Alexion Pharmaceuticals's stock gained $7.04 to close up 6.4% at $116.70 per share on 24 October after the company said Soliris (eculizumab) sales increased 36% in the third quarter to $400.4m – beating the $395m stock analyst consensus – from $294.1m during the same period in 2012. Alexion's market cap is $22.8bn.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.